Innocan Pharma Corp
CNSX:INNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innocan Pharma Corp
CNSX:INNO
|
IL |
|
S
|
Stelco Holdings Inc
OTC:STZHF
|
CA |
|
Jaiprakash Associates Ltd
NSE:JPASSOCIAT
|
IN |
|
Aptus Value Housing Finance India Ltd
NSE:APTUS
|
IN |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
CA |
|
Pexip Holding ASA
F:4W9
|
NO |
|
Balyo SA
PAR:BALYO
|
FR |
|
J Sainsbury PLC
LSE:SBRY
|
UK |
|
Suzhou Alton Electrical & Mechanical Industry Co Ltd
SZSE:301187
|
CN |
|
Tekcapital PLC
LSE:TEK
|
UK |
|
Shenandoah Telecommunications Co
NASDAQ:SHEN
|
US |
|
Jagsonpal Pharmaceuticals Ltd
NSE:JAGSNPHARM
|
IN |
|
A
|
Azorim Investment Development and Construction Co Ltd
TASE:AZRM
|
IL |
|
H
|
Huaibei Mining Holdings Co Ltd
SSE:600985
|
CN |
|
United States Lime & Minerals Inc
NASDAQ:USLM
|
US |
|
N
|
Nakayo Inc
TSE:6715
|
JP |
|
V
|
Vinci SA
OTC:VCISF
|
FR |
|
N
|
Nueva Expresion Textil SA
MAD:NXT
|
ES |
|
Technical Communications Corp
OTC:TCCO
|
US |
|
L
|
Lundin Energy AB
XBER:LYV
|
SE |
Innocan Pharma Corp
InnoCan Pharma Corp. focuses on the development and sale of CBD-integrated pharmaceuticals including topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
InnoCan Pharma Corp. focuses on the development and sale of CBD-integrated pharmaceuticals including topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
